SABR-COMET: a new paradigm of care lights up the twilight of metastatic disease

Paolo Sogono¹, David L Ball^{1

2}, Shankar Siva^{1

2}

Affiliations

¹ Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
² Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.

Editorial

Paolo Sogono et al. Ann Transl Med. 2019 Nov.

. 2019 Nov;7(22):615.

doi: 10.21037/atm.2019.10.96.

Paolo Sogono¹, David L Ball^{1

2}, Shankar Siva^{1

2}

¹ Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
² Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Australia.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.
Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, Schellenberg D, Ahmad B, Griffioen G, Senthi S, Swaminath A, Kopek N, Liu M, Moore K, Currie S, Bauman GS, Warner A, Senan S. Palma DA, et al. Lancet. 2019 May 18;393(10185):2051-2058. doi: 10.1016/S0140-6736(18)32487-5. Epub 2019 Apr 11. Lancet. 2019. PMID: 30982687 Clinical Trial.

1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995;13:8-10. 10.1200/JCO.1995.13.1.8 - DOI - PubMed
1. Barney JD, Churchill EJ. Adenocarcinoma of the Kidney with Metastasis to the Lung: Cured by Nephrectomy and Lobectomy. Journal of Urology 1939;42:269-76. 10.1016/S0022-5347(17)71516-9 - DOI
1. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322:494-500. 10.1056/NEJM199002223220802 - DOI - PubMed
1. Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 2019;393:2051-8. 10.1016/S0140-6736(18)32487-5 - DOI - PubMed
1. Rubinstein LV, Korn EL, Freidlin B, et al. Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol 2005;23:7199-206. 10.1200/JCO.2005.01.149 - DOI - PubMed